Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3676
Structure:
Synonyms:
"lidocaine (73-58-6 (monohydrochloride); 6108-05-0 (monohydrochloride monohydrate))"
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2',6'-Acetoxylidide, 2-(diethylamino)-
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0
6108-05-0 (mono-hydrochloride, mono-hydrate)
6108-05-0 (MONOHYDROCHLORIDE
73-78-9
73-78-9 (mono-hydrochloride)
8059-42-5
8059-66-3
91484-71-8
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
ALPHACAINE
Anestacon
Anestacon Jelly
ARONIS23855
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CCG-100824
CDS1_000283
CHEBI:6456
CHEMBL79
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
EMLA
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS2235O14
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LANABIOTIC
Leostesin
Lida-Mantle
Lidaform-HC
Lidamantle-HC
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); 6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
Lidocaine (JP15/USP/INN)
Lidocaine (JP16/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
LS-805
Maricaine
Maybridge1_002571
Mixture Name
MLS000069724
MLS000758263
MLS001074177
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-05
NCGC00015611-06
NCGC00015611-07
NCGC00015611-08
NCGC00015611-09
NCGC00015611-10
NCGC00015611-11
NCGC00015611-12
NCGC00015611-13
NCGC00015611-14
NCGC00015611-15
NCGC00015611-16
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
Neosporin Plus
NINDS_000174
Norwood Sunburn Spray
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Oraqix
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
ROCEPHIN KIT
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
ST023341
STK552033
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
ATC-Codes:
Side-Effects:
Side-EffectFrequency
asthenia0.0010
pain0.0010
paresthesia0.0010
cardiovascular collapse0.0010
tinnitus0.0010
tremors0.0010
unconsciousness0.0010
vomiting0.0010
lightheadedness0.0010
blurred vision0.0010
bradycardia0.0010
numbness0.0010
nervousness0.0010
confusion0.0010
convulsions0.0010
double vision0.0010
dizziness0.0010
somnolence0.0010
flushing0.0010
headache0.0010
hyperesthesia0.0010
hypotension0.0010
nausea0.0010
seizures0
burning sensation0
urinary retention0
gingivitis0
meningismus0
petechiae0
dermatitis0
tachycardia0
ventricular fibrillation0
skin irritation0
weakness0
dyspnea0
neuropathy0
anaphylaxis0
anxiety0
apprehension0
euphoria0
excitement0
hyperacusis0
allergic reaction0
hemorrhage0
infection0
increased sweating0
sneezing0
meningitis0
venous thrombosis0
syncope0
unconsciousness0
urticaria0
fever0
apnea0
acidosis0
hypopigmentation0
bronchospasm0
angioedema0
back pain0
agitation0
phlebitis0
atrial flutter0
erythema0
dysarthria0
chills0
respiratory arrest0
blistering0
paralysis0
cardiac arrest0
hypertension0
edema0
vascular disorders0
urinary incontinence0
heart block0
arachnoiditis0
hypersensitivity0
stomatitis0
sore throat0
methemoglobinemia0

Target

show target details
Uniprot ID:CP2D6_HUMAN
Synonyms:
CYPIID6
Cytochrome P450 2D6
Debrisoquine 4-hydroxylase
P450-DB1
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2F9Q
Structure:
2F9Q

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----
----
----
----

References:

15845683
The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine.. Klaus T Olkkola; Mika H Isohanni; Katri Hamunen; Pertti J Neuvonen (2005) Anesthesia and analgesia display abstract
Inhibitors of CYP3A4 (cytochrome P450 3A4) have a minor effect on lidocaine pharmacokinetics. We studied the effect of coadministration of the antidepressant fluvoxamine (CYP1A2 inhibitor) and antimicrobial drug erythromycin (CYP3A4 inhibitor) on lidocaine pharmacokinetics in a double-blind, randomized, three-way crossover study. Nine volunteers ingested daily 100 mg fluvoxamine and placebo, 100 mg fluvoxamine and 1500 mg erythromycin, or their corresponding placebos for 5 days. On day 6, 1.5 mg/kg lidocaine was administered IV over 60 min. Concentrations of lidocaine and its major metabolite monoethylglycinexylidide were measured for 10 h. Fluvoxamine alone decreased the clearance of lidocaine by 41% (P < 0.001) and prolonged its elimination half-life from 2.6 to 3.5 h (P < 0.01). During the combination of fluvoxamine and erythromycin, lidocaine clearance was 53% smaller than during placebo (P < 0.001) and 21% smaller than during fluvoxamine alone (P < 0.05). During the combination phase the half-life of lidocaine (4.3 h) was longer than during the placebo (2.6 h; P < 0.001) or fluvoxamine (3.5 h; P < 0.01). We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces elimination of lidocaine and may increase the risk of lidocaine toxicity. Concomitant use of both fluvoxamine and a CYP3A4 inhibitor such as erythromycin can further increase plasma lidocaine concentrations by decreasing its clearance.
8068867
8250975
8516899
8565792
Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats.. Y Masubuchi; C Takahashii; N Fujio; T Horie; T Suzuki; S Imaoka; Y Funae; S Narimatsu (1995) Drug metabolism and disposition: the biological fate of chemicals display abstract
Repetitive oral administration of imipramine (100 mg/kg/day for 5 days) caused a decrease in rat liver microsomal debrisoquine 4-hydroxylase activity, a characteristic reaction catalyzed by cytochrome P450 (CYP) 2D1. Other CYP2D-dependent reactions (such as bunitrolol 4-hydroxylation, lidocaine 3-hydroxylation, and propranolol 4-, 5- and 7-hydroxylations) were also impaired by the treatment, but not those catalyzed by other CYP isozymes. Imipramine pretreatment did not change the immunochemically determined content of the CYP2D protein, suggesting that CYP2D is inactivated. Imipramine pretreatment also resulted in an increase in total CYP content and in formation of a ferrous CYP metabolic intermediate (MI)-complex absorbing at 454 nm. Although the total CYP content was increased by the treatment of these microsomes with ferricyanide to dissociate the MI-complex, the CYP2D-dependent activities were not restored, suggesting that the MI-complex was not the primary cause of CYP2D inhibition. This pretreatment regimen caused marked increases in immunochemically determined levels of CYP2A1, CYP2B1, CYP2B2, CYP2C6, and CYP3A2, and in the activities of 2 alpha-, 2 beta-, 6 beta-, 7 alpha-, 16 alpha-, and 16 beta-hydroxylation and 17-oxidation of testosterone. These results indicate that imipramine has two actions on the liver CYP system (i.e. as an inhibitor of the CYP2D enzyme and as a phenobarbital-type inducer).
9143866